羅替戈汀為選擇性多巴胺D1/D2/D3受體激動劑，其透皮貼劑是第一個非麥角類多巴胺受體激動劑貼劑。羅替戈汀貼劑24 h有效，能對帕金森病人持續(xù)提供多巴胺能刺激，目前獲得FDA和EMA批準上市。對羅替戈汀貼劑研究情況進行簡要綜述。

Rotigotine transdermal patch is the first transdermal non-ergot dopamine agonist, which is a selective dopamine D1/D2/D3 receptor agonist. Rotigotine patch is effective over 24 h providing a continuous dopaminergic stimulation in patients with Parkinson’s disease (PD) and is approved for use in treatment of PD by the FDA and EMA. This paper is a review of current status of Rotigotine transdermal patch.